PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
May 02, 2019
Translarna™ Approved by Brazilian Health Regulatory Authority (ANVISA) Waylivra™ Receives Positive CHMP Opinion SOUTH PLAINFIELD, N.J. , May 2, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending
Additional Formats
Apr 29, 2019
- Ambulatory Duchenne patients who are 5 years and older with a nonsense mutation can now access a treatment that targets the underlying cause - SOUTH PLAINFIELD, N.J. , April 29, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna ™  (ataluren) has been
Additional Formats
Apr 18, 2019
SOUTH PLAINFIELD, N.J. , April 18, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2019 financial results and provide an update on the company's business and outlook on Thursday, May 2, 2019
Additional Formats
Mar 04, 2019
SOUTH PLAINFIELD, N.J. , March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company 39 th Annual Health Care Conference Monday, March 11 th at 11:20 a.m.
Additional Formats
Mar 04, 2019
WAYLIVRA, the first and only therapy for the treatment of familial chylomicronemia syndrome (FCS), has received a positive opinion from the CHMP SOUTH PLAINFIELD, N.J. , March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics ,
Additional Formats
Mar 01, 2019
SOUTH PLAINFIELD, N.J. , March 1, 2019 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on February 25, 2019 it approved non-statutory stock options to purchase an aggregate of 125,000 shares of its common stock to 20 new employees.
Additional Formats
Feb 28, 2019
SOUTH PLAINFIELD, N.J. , Feb. 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2018 . "We are proud to be in the strong position of having a growing revenue base
Additional Formats
Feb 25, 2019
SOUTH PLAINFIELD, N.J. , Feb. 25, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the sole underwriter of its previously announced public offering of 6,720,000 shares of its common stock, which closed on January 25, 2019 , has partially exercised its option to
Additional Formats
Feb 14, 2019
SOUTH PLAINFIELD, N.J. , Feb. 14, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2018 financial results and provide an update on the company's business and outlook on
Additional Formats
Feb 13, 2019
- STRIVE Awards have Supported Over 20 Projects in 15 Countries- -Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30- SOUTH PLAINFIELD, N.J. , Feb. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the fifth annual STRIVE grant
Additional Formats